Bindarit , ≥98% , 130641-38-2
| Pack Size | Price | Stock | Quantity |
| 5MG | RMB396.80 | In Stock |
|
| 10MG | RMB756.80 | In Stock |
|
| 50MG | RMB2212.00 | In Stock |
|
| others | Enquire |
PRODUCT Properties
| Boiling point: | 542.9±40.0 °C(Predicted) |
| Density | 1.18±0.1 g/cm3 (20 ºC 760 Torr) |
| storage temp. | 2-8°C |
| solubility | DMSO:47.0(Max Conc. mg/mL);144.89(Max Conc. mM) |
| form | A crystalline solid |
| pka | 3.59±0.10(Predicted) |
| color | White to off-white |
Description and Uses
Bindarit is an inhibitor of monocyte chemoattractant protein (MCP) production that is selective for MCP-1/CCL2, MPC-3/CCL7, and MCP-2/CCL8 over other chemokines. It inhibits LPS- or C. albicans-induced production of MCP-1/CCL2 in isolated human monocytes (IC50s = 172 and 403 μM, respectively). Bindarit downregulates NF-κB signaling and prevents p65 and p65/p50-mediated MCP-1/CCL2 promoter activation in RAW264.7 cells. It delays the onset of proteinuria and prolongs survival in a mouse model of experimental lupus nephritis when administered at a dose of 50 mg/kg. It prevents LPS-induced increases in MCP-1/CCL2 expression in mouse brain and spinal cord when administered at a dose of 200 mg/kg and reduces the incidence and severity of experimental autoimmune encephalomyelitis (EAE) in mice. Bindarit is also a noncompetitive inhibitor of monocarboxylate transporter 4 (MCT4; Ki = 30.2 μM for the human transporter) that is selective for MCT4 over MCT1.
Bindarit shows anti-inflammatory activity due to a selective inhibition of a subfamily of inflammatory chemokines. Bindarit is a also protein antidenaturant agent. Bindarit modulates the NFkB pathway and has been shown to reduce secondary phase of adjuvant arthritis in rats.
Safety
| Symbol(GHS) |  GHS07 |
| Signal word | Warning |
| Hazard statements | H302-H315-H319-H335 |
| Precautionary statements | P261-P280-P301+P312-P302+P352-P305+P351+P338 |
